@article{960809a2481b478599e3b89e92bc9933,
title = "Re: {\textquoteleft}Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes{\textquoteright}—Author's reply",
author = "A. Nutman and Y. Carmeli",
note = "Funding Information: The authors declare no competing interests. Y. C. has received research funding from MSD, AstraZeneca, Allecra Therapeutics, DaVoltera, Intercell AG, bioM{\'e}rieux SA, Rempex Pharmaceuticals, Nariva, Achoagen, Roche, Pfizer, and Shionogi.",
year = "2020",
month = sep,
doi = "10.1016/j.cmi.2020.05.010",
language = "אנגלית",
volume = "26",
pages = "1275",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Ltd.",
number = "9",
}